WASHINGTON – U.S. Senator Mike Crapo (R-Idaho), Ranking
Member of the U.S. Senate Finance Committee, delivered the following remarks at
a nomination hearing for Andrea Palm to be HHS Deputy Secretary, and Chiquita
Brooks-LaSure to be CMS Administrator.
The text of Ranking Member
Crapo’s remarks, as prepared, is below.
“When
we held our hearing for Xavier Becerra to be the Secretary of Health and Human
Services, I noted the size and importance of the Department he would lead.
“In
normal times, HHS and its agencies provide health care coverage to nearly 150
million people, and those agencies affect the lives of many more on a daily
basis.
“The
COVID-19 pandemic has raised the salience of the Department.
“The
Department’s leadership, including the Deputy Secretary, will continue to play
a key role in bringing us out of the Public Health Emergency.
“Similarly,
Medicare and Medicaid are providing essential health care to patients who have
suffered disproportionately from the COVID-19 pandemic.
“Looking
to the future, the Secretary, the Deputy Secretary and the CMS Administrator
must carefully evaluate how best to use the resources available to them to
promote the health care of our citizens.
“They
must do so carefully, constructively, and creatively.
“Two
months ago, I outlined several issues in the health care space where I intend
to focus my efforts as Ranking Member, including fostering innovation to
improve patient care and make our health care system more efficient.
“The
COVID-19 pandemic has threatened Americans’ physical and economic health, but
it has also reinforced the value of innovation and provided an opportunity to
test changes that foster it.
“HHS
has used its authority under the Public Health Emergency to waive numerous
requirements to ensure Medicare and Medicaid beneficiaries and other patients
receive care during the pandemic.
“Patients
and providers have benefited from expanded access to telehealth and expedited
approval of COVID-19 vaccines, diagnostics and treatments.
“Going
forward, Medicare and Medicaid patients must have the same access to innovative
items and services as those with commercial insurance.
“We
must carefully evaluate our response to the pandemic and implement appropriate
reforms based on the lessons we have learned.
“HHS
should partner with this Committee in that effort.
“However,
media reports about certain health care policies that may come before Congress,
or be enacted through executive actions, are concerning.
“Some
of these policies, such as including additional benefits under Medicare, could
experience bipartisan support if considered through a transparent, cooperative
process.
“Unfortunately,
reconciliation does not afford Congress the opportunity to work together to
evaluate these changes and make necessary reforms to protect the long-term
financial viability of the program.
“Other
policies, such as expanding Obamacare’s premium subsidy to everyone, regardless
of income, would be incredibly expensive for taxpayers without taking
appropriate steps to lower the cost of health insurance.
“Creative,
bipartisan ideas to lower the cost of insurance in the individual market have
been raised by states and my colleagues on this Committee.
“I
welcome the opportunity to work together on some of these ideas, such as
allowing states to use waivers to their full potential, diversifying benefit
designs and incentivizing competition.
“Finally,
I am concerned about paying for some of these policies through changes to our drug
pricing system that could stifle innovation.
“We
can see the end of the COVID-19 pandemic approaching, thanks to groundbreaking
vaccines developed by pharmaceutical manufacturers.
“In
this crisis, industry responded to the nation’s call-to-arms, codenamed ‘Project
Warp Speed,’ developing powerful and effective vaccines in record time.
“This
success was possible because of the private sector.
“I
strongly agree with my colleagues that this innovation is only valuable if
patients can afford it.
“We
should establish an out-of-pocket spending cap and reform Medicare Part D with
the market-based principles of competition and transparency in mind.
“Ms.
Palm and Ms. Brooks-LaSure, if you are confirmed, I look forward to working
with you to improve our health care system.
“I
ask you to commit to careful assessments of the risks and considerations in
every policy decision you make.
“Political
pressures may make unilateral action seem attractive, but you should also
consider how the market, individual choice, public policy, and incentives play
vital roles in the development and delivery of health care.
“I
look forward to hearing your testimony and your responses to questions.
“The
positions to which you have been nominated have substantial influence over
policy.
“The
members of this Committee need to understand how you will implement the
Administration’s agenda.
“We expect
your answers, here and in response to QFRs, to be detailed and candid.”